Sarepta price target raised to $196 from $195 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Sarepta (SRPT) to $196 from $195 and keeps an Overweight rating on the shares. Q4 revenues highlighting “robust” Elevidys growth were pre-announced, and 2025 guidance was reiterated, notes the analyst, who expects strong Elevidys launch momentum to continue and thinks multiple catalysts later this year could drive “additional upside.”